U.S. FDA expected to approve Pfizer COVID-19 vaccine for children 12 to 15 by next week


The U.S. Food and Drug Administration (FDA) is expected to authorize Pfizer’s COVID-19 vaccine for young adults age 12 and older by next week, according to a federal official and a person familiar with the process, setting up shots for many before the beginning of the next school year.

The announcement is set to come barely a month after the company found that its shot, which is already authorized for those age 16 and older, also provided protection for the younger group.

Read more:
Pfizer asks European Union to approve vaccine for kids aged 12 to 15

The federal official, speaking on the condition of anonymity to preview the FDA’s action, said the agency was expected to expand its emergency use authorization for Pfizer’s two-dose vaccine by early next week, and perhaps even sooner. The person familiar with the process, who spoke on condition of anonymity to discuss internal matters, confirmed the timeline and added that it is expected that the FDA will approve Pfizer’s use by even younger children sometime this fall.

Story continues below advertisement

The FDA action will be followed by a meeting of a federal vaccine advisory committee to discuss whether to recommend the shot for 12- to 15-year-olds. Shots could begin after the Centers for Disease Control and Prevention adopts the committee’s recommendation. Those steps could be completed in a matter of days.

Click to play video: 'What’s the latest on a vaccine for kids? Doctor answers your COVID-19 questions.'

What’s the latest on a vaccine for kids? Doctor answers your COVID-19 questions.

What’s the latest on a vaccine for kids? Doctor answers your COVID-19 questions.

The New York Times first reported on the expected timing for the authorization.

Pfizer in late March released preliminary results from a vaccine study of 2,260 U.S. volunteers ages 12 to 15, showing there were no cases of COVID-19 among fully vaccinated adolescents compared with 18 among those given dummy shots.

Kids had side effects similar to young adults, the company said. The main side effects are pain, fever, chills and fatigue, particularly after the second dose. The study will continue to track participants for two years for more information about long-term protection and safety.

Story continues below advertisement

Pfizer isn’t the only company seeking to lower the age limit for its vaccine. Results also are expected by the middle of this year from a U.S. study of Moderna’s vaccine in 12- to 17-year-olds.

Read more:
Canada set to receive 1 million more Moderna doses in May as Ontario marks 8K deaths

But in a sign that the findings were promising, the FDA already allowed both companies to begin U.S. studies in children 11 and younger, working their way to as young as 6 months old.

More than 131 million doses of Pfizer’s vaccine have already been administered in the U.S., where demand for vaccines among adults has dramatically slowed in recent weeks.

While younger people are at dramatically lower risk of serious side effects from COVID-19, they have made up a larger share of new virus cases as a majority of U.S. adults have been at least partially vaccinated and as higher-risk activities like indoor dining and contact sports have resumed in most of the country. Officials hope that extending vaccinations to teens will further accelerate the nation’s reduced virus caseload and allow schools to reopen with minimal disruptions this fall.

The U.S. has ordered at least 300 million doses of the Pfizer shot by the end of July, enough to protect 150 million people.

What has Health Canada said?

In a statement emailed to Global News, a spokesperson for Health Canada confirmed the agency received a submission from Pfizer-BioNTech to “expand the use of its COVID-19 vaccine to individuals 12 years of age and older” on April 16.

Story continues below advertisement

“The Department is currently reviewing the submission and will only issue a decision following a thorough scientific review of the vaccine’s safety and efficacy in this younger age group,” the email read. “As with all COVID-19 submissions, Health Canada is expediting this review. ”

However, the agency said “at this time, we cannot provide specific timelines for completion.”

Currently, the Pfizer-BioNTech COVID-19 vaccine has been approved for use in those 16 and older in Canada.

-With files from Global News’ Hannah Jackson

© 2021 The Canadian Press